Аутологичная трансплантация гемопоэтических стволовых клеток у больных с впервые диагностированной множественной миеломой

Аутологичная трансплантация гемопоэтических стволовых клеток у больных с впервые диагностированной множественной миеломой

Автор: Бессмельцев С.С.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Передовая статья

Статья в выпуске: 1 т.19, 2023 года.

Бесплатный доступ

Множественная миелома (ММ) - это гетерогенное заболевание, определяемое клональной пролиферацией плазматических клеток, гематологическая опухоль, которая составляет 1,0-1,8% среди всех видов онкологических заболеваний. В последние десятилетия в результате широкого применения аутологичной трансплантации гемопоэтических стволовых клеток (АутоТГСК) и новых, весьма эффективных лекарственных средств, существенно улучшились показатели выживаемости пациентов с множественной миеломой. Для пациентов

Множественная миелома, бортезомиб, леналидомид, моноклональные антитела, аутологичная трансплантация гемопоэтических стволовых клеток, полный ответ, общая выживаемость

Короткий адрес: https://sciup.org/170199720

IDR: 170199720

Список литературы Аутологичная трансплантация гемопоэтических стволовых клеток у больных с впервые диагностированной множественной миеломой

  • Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: рук. для врачей. – М.: МК. 2016. – 504.
  • Moreau P., San Miguel J., Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. – 2017. – Vol. 28, Suppl 4. – P. iv52–61.
  • Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020 // Cancer J Clin. – 2020. – Vol. 70. – P. 7–30.
  • Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic Lymphoid Tissues. Lyon: IARC Press, 2001.
  • Злокачественные новообразования в России в 2017 году (заболеваемость и смертность)./ под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
  • Tricot G. New insights into role of microenvironment in multiple myeloma // Lancet. – 2000. – Vol. 355, N 9200. – P. 248-50
  • SEER Cancer Stat Facts: Myeloma. Bethesda: National Cancer Institute. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 24 Feb 2020.
  • Fonseca R., Usmani S.Z., Mehra M. et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. - BMC Cancer. – 2020. – Vol. 20. – P. 1087-1098.
  • Kumar S.K., Callander N.S., Alsina M. et al. NCCN guidelines insights: multiple myeloma, version 3.2018// J Natl Compr Canc Netw. – 2018. – Vol. 16. – P. 11–20.
  • Бессмельцев С.С. Множественная миелома: диагностика и терапия (часть 1)//Вестник гематологии. - 2022. - Т. 18, №2. - С. 4-26.
  • Dimopoulos M. A., Moreau P., Terpo E. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals Oncology. – 2021. – Vol. 32. – P. 309-322.
  • Shaji K. Kumar, Natalie S. et al. Multiple Myeloma, Version 3.2021. NCCN Clinical Practice Guidelines in Oncology // J Natl Compr Canc Netw . – 2020. – Vol. 18, N 12. – P. 1685–1717.
  • NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 4.2022 — December 14, 2021/ Shaji K. Kumar, Natalie S. et al.
  • Михайлов Е.С., Салогуб Г.Н., Бессмельцев С.С. Влияние возраста на результаты аутологичной трансплантации гемопоэтических стволовых клеток у пациентов с множественной миеломой // Биомедицинскийжурнал Medline.ru. – 2021. – Т. 22, СТ. 36. – С. 527-539.
  • Muchtar E., Dingli D., Kumar S. et al., Autologous stem cell transplant for multiple myeloma patients 70 years or older // Bone Marrow Transplant. – 2016. – Vol. 51, N 11. – P. 1449-1455.
  • Charlson M. Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index // J Clin Epidemiol. - 1994. – Vol. 47, N 11. – P. 1245-1251.
  • Saad A., Mahindra A., Zhang M.-J. et al., Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma // Biol Blood Marrow Transplant. - 2014. – Vol. 20, N 3. – P. 402-408 e1.
  • Грицаев С.В., Кузяева А.А., Бессмельцев С.С. Отдельные аспекты трансплантации аутологичных гемопоэтических стволовых клеток больным множественной миеломой // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. – 2017. – № 1. – С. 7–12.
  • Gertz M.A. Current status of stem cell mobilization // Br. J. Haematol. – 2010. – 150. – P. 647–662.
  • Milone G., Martino M., Spadaro A. et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs // Br. J. Haematol. – 2014. – Vol. 164. – P. 113–123.
  • Costa L., Abbas J., Hogan K. et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure // Bone. Marrow. Transplant. – 2012. – Vol. 47. – P. 1403–1408.
  • Martino M., Tripepi G., Messina G. et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy // Bone Marrow Transplant. – 2016. – Vol. 51, N 9. – P. 1197-11203.
  • Saini N., Bashir O., Milton D. et al. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM // Blood. Adv. – 2020. – Vol. 4. – P. 4834–4837.
  • Roussel M., Lauwers-Cances V., Macro M. et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study // Blood. 2022. – Vol. 139. – P. 2747–2757.
  • Costa L., Landau H., Chhabra S. et al. Phase 1/2 trial of carfilzomib plus high-dose melphalan preparative regimen for salvage autologous hematopoietic cell transplantation followed by maintenance carfilzomib in patients with relapsed/refractory multiple myeloma // Biol. Blood. Marrow. Transplant. – 2018. – Vol. 24. – P. 1379–1385.
  • Attal M., Harousseau J.L., Stoppa A.M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome // N Engl J Med. – 1996. – Vol. 335. – P. 91-97.
  • Child J.A., Morgan G.J., Davies F.E. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. // N Engl J Med. – 2003. – Vol. 348. – P. 1875-1883.
  • Barlogie B., Kyle R.A., Anderson K.C. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 // J Clin Oncol. – 2006. – Vol. 24. – P. 929- 936.
  • Moreau P., Facon T., Attal M. et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial //. Blood. – 2002. – Vol. 99. – P. 731-735.
  • Palumbo A., Cavallo F., Gay F. et al., Autologous transplantation and maintenance therapy in multiple myeloma // N Engl J Med. - 2014. Vol. 371, N 10. – P. 895-905.
  • Richardson P.G., Weller E., Lonial S. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma// Blood. – 2010. – Vol. 116. – P. 679-686
  • Roussel M., Lauwers-Cances V., Robillard N. et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome // J Clin Oncol. – 2014. – Vol. 32. – P. 2712-2717.
  • Kumar S., Flinn I., Richardson P.G. et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma // Blood. – 2012. – Vol. 119. – P. 4375-4382.
  • Goicoechea E., Puig N., Cedenae M. et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma // Blood. 2021. – Vol. 137. – P. 49-60.
  • Чубукина Ж.В., Глазанова Т.В., Кострома И.И., Бубнова Л.Н., Грицаев С.В., Волошин С.В., Бессмельцев С.С. Динамика минимальной остаточной болезни у больных множественной миеломой до и после трансплантации аутологичных гемопоэтических стволовых клеток // Вестник гематологии. – 2019. – Т. 15, №3. – С. 71.
  • Attal M., Lauwers-Cances V., Hulin C. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma // N Engl J Med. – 2017. – Vol. 76. – P. 1311-1320.
  • Cavo M., Gay F., Patriarca F. et al. Double autologous stem cell trans- plantation significantly prolongs progressionfree survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study // Blood. – 2017. – Vol. 130, Suppl 1. – P. 401.
  • Cavo M., Gay F., Beksac M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalanprednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study // Lancet Haematol. – 2020. – Vol. 7. – P. e456-e468.
  • Dhakal B., Szabo A., Chhabra S. et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis // JAMA Oncol. – 2018. – Vol. 4, N3. – P. 343-350.
  • Gay F., Cerrato C., Petrucci M. et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial // J Clin Oncol. – 2019. – Vol. 37, Suppl 15. – P. 8002.
  • Gay F., Musto P., Rota-Scalabrini D. et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial // Lancet Oncol. – 2021. – Vol. 22. – P. 1705–1720.
  • Rajkumar S.V. Myeloma today: Disease definitions and treatment advances // Am J Hematol. – 2016. – Vol. 91, N 1. – P. 90-100.
  • Бессмельцев С.С. Анти-CD38 моноклональные антитела в лечении рецидивов/рефрактерных форм множественной миеломы // Вестник гематологии. -2018. – Т. XIV, № 3. – C. 5-18.
  • Deckert J., Wetzel M.C., Bartle L.M. et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 hematologic malignancies // Clin Cancer Res. - 2014. – Vol. 20, N17. – P. 4574–4583.
  • van de Donk W.C.J., Richardson P., Malavasi F. CD38 antibodies in multiple myeloma: back to the future // Blood. - 2018. – Vol. 131, N1. – P. 13–29.
  • Moreau P., Attal M., Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study // Lancet. – 2019. – Vol. 394. – P. 29-38.
  • Voorhees P.M., Kaufman J.L., Laubach J. et al. Daratumumab, lenalido- mide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial // Blood. – 2020. – Vol. 136. – P. 936–945.
  • Landgren O., Hultcrantz M., Diamond B. et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma. The MANHATTAN Nonrandomized Clinical Trial // JAMA Oncol. - 2021. – Vol. 7, N 6. – P. 862-868.
  • Costa L.J., Chhabra S., Medvedova E. et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma // Journal of Clinical Oncology. - Published online December 13, 2021.DOI: 10.1200/JCO.21.01935.
  • Attal M., Harousseau J-L., Facon Th. et al. Single versus double autologous stem-cell transplantation for multiplemyeloma // N Engl J Med. – 2003. – Vol. 349, N 26. – P. 2495-2502.
  • Cavo M. Tosi P., Zamagni E. et al., Prospective, randomized study of single compared with double autologous stemcell transplantation for multiple myeloma: Bologna 96 clinical study // J Clin Oncol. - 2007. – 25, N 17. – P. 2434-2441.
  • Kumar A. Kharfan-Dabaja M.A., Glasmacher A., Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis // J Natl Cancer Inst. - 2009. – Vol. 101, N 2. – P. 100-106.
  • Giralt S. Vesole D.H., George Somlo G. et al., Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis // J Natl Cancer Inst. - 2009. – Vol. 101, N 13. – P. 964; author reply 966-967.
  • Barlogie B., Attal M., Crowley J. et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of Arkansas for medical sciences // J Clin Oncol. – 2010. – Vol. 28. – P. 1209-1214.
  • Stadtmauer A., Pasquini M., Blackwell B. et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with Multiple Myeloma (MM): Primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) // ASH Annual meeting 2016 ; Late breaking Abstract.
  • Stadtmauer E.A., Pasquini M.C., Blackwell B. et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial // J Clin Oncol. – 2019. – Vol. 37. – P. 589-597.
  • Hari P., Pasquini M., Stadtmauer E. et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of post autologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) // J Clin Oncol. – 2020. – Vol. 38, Suppl 15. – P. 8506.
  • NCCN Clinical practice guidelines in oncology. Multiple Myeloma, Version 3.2021/ Kumar S.K., Callander N.S., Adekola K. et al.
  • Touzeau C., Perrot A., Hulin C. et al Daratumumab, carfilxomib, lenalidomide and dexamethasone as induction therapy in high-risk transplantat eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04// ASCO 2022, Abstract 8002
  • Cavo M., et al., Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma. 60th ASH Annual Meeting & Exposition, 2018: p. abstract 124.
  • Fotaki V. ASH 2018 | Long-term follow-up of double vs single ASCT in patients with newly diagnosed multiple myeloma/ The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. On Saturday 1 December 2018, an oral abstract session was held entitled: Clinical Autologous Transplantation: Results: Multiple Myeloma: Upfront Autologous Transplantation, which focused on updates of advanced clinical trials for newly diagnosed multiple myeloma (NDMM).
  • Fermand J. P., Ravaud P., Chevret S. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial // Blood. – 1998. – Vol. 92, N 9. – P. 3131–3136.
  • Barlogie B., Kyle R.A., Anderson K.C. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 //J. Clin. Oncol. – 2006. – Vol. 24, N 6. – P. 929–936.
  • Cook G., Liakopoulou E., Pearce R. et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry // Biol Blood Marrow Transplant. – 2011. – Vol. 17. – P. 1638- 1645.
  • Attal M., Lauwers-Cances V., Hulin C. et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myeloma (IFM/DFCI 2009 Trial) // Blood. – 2015. – Vol. 126. – P. 391.
  • Rajkumar S.V., Kumar S. Multiple myeloma current treatment algorithms // Blood Cancer Journal. – 2020. – Vol. 94. – P. 2-10.
Еще
Статья научная
SciUp 2024 © 2024 ©